Estela Rodriguez, Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, shared a post on X:
“Happy Monday!
FDA Oncology grants accelerated approval to Dato-Dxd datopotamab deruxtecan (Trop-2 ADC) for previously treated EGFR+ NSCLC based on TROPION Lung01, 05
ORR of 42.7%, mDoR 7.0 mos
mOS 15.6 mos
AEs: Nausea, stomatitis, ILD.”
More posts featuring Estela Rodriguez.